Factors Associated with Successful Discontinuation of Oral Antivirals in Chronic HBV

In a systematic review, HBeAg-negative patients were more likely to maintain remission if they had already been in remission for 2 years while on therapy.

In the treatment of patients with hepatitis B e antigen (HBeAg)–negative chronic hepatitis B virus (HBV) infection with oral antiviral drugs, the expectation is that treatment will be indefinite and that only a minority of HBeAg-positive patients will be able to discontinue therapy.

In a systematic review, investigators evaluated factors associated with long-term viral remission (VR) in patients with HBV infection (HBeAg-positive and HBeAg-negative) in whom oral antiviral therapy was discontinued. Duration of therapy was >12 months and post-therapy follow-up was ≥12 months.

Among 25 studies (randomized trials and observational studies; published 2002–2014) comprising 1716 patients, durable VR (lasting >12 months post-therapy) was reported in …

Reviewing Author

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Factors Associated with Successful Discontinuation of Oral Antivirals in Chronic HBV

Topics

Reviewing Author